Crossref
FDA approval of Deuruxolitinib: A New Treatment Option for Severe Alopecia Areata
Clinical Research · 15.11.2024 · 5 (1)
DOI: 10.35702/clinres.10023 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Research, online erschienen am 15.11.2024. Verfasst von Tooba Javed. Die Arbeit wurde bisher 7-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Javed, T. (2024). FDA approval of Deuruxolitinib: A New Treatment Option for Severe Alopecia Areata. Clinical Research, 5(1). https://doi.org/10.35702/clinres.10023
Vancouver
Javed T. FDA approval of Deuruxolitinib: A New Treatment Option for Severe Alopecia Areata. Clinical Research. 2024;5(1). doi:10.35702/clinres.10023
BibTeX
@article{Javed2024,
author = {Javed, Tooba},
title = {FDA approval of Deuruxolitinib: A New Treatment Option for Severe Alopecia Areata},
journal = {Clinical Research},
year = {2024},
volume = {5},
number = {1},
doi = {10.35702/clinres.10023}
}
EUVIMED